Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
SEC Accession No. 0001610520-24-000153
Filing Date
2024-09-05
Accepted
2024-09-05 15:28:10
Documents
1
Period of Report
2024-08-27

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_doc.html 4/A  
1 PRIMARY DOCUMENT primary_doc.xml 4/A 4356
  Complete submission text file 0001610520-24-000153.txt   6189
Mailing Address BAHNHOFSTRASSE 45 ZURICH V8 CH-8001
Business Address BAHNHOFSTRASSE 45 ZURICH V8 CH-8001 41-44-234-1111
UBS Group AG (Reporting) CIK: 0001610520 (see all company filings)

State of Incorp.: V8 | Fiscal Year End: 1231
Type: 4/A | Act: 34 | File No.: 001-37969 | Film No.: 241281185
SIC: 6021 National Commercial Banks
(CF Office: 02 Finance)

Mailing Address 3600 GREEN COURT SUITE 350 ANN ARBOR MI 48105
Business Address 3600 GREEN COURT SUITE 350 ANN ARBOR MI 48105 734-335-0468
ENDRA Life Sciences Inc. (Issuer) CIK: 0001681682 (see all company filings)

EIN.: 260579295 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 3845 Electromedical & Electrotherapeutic Apparatus
(CF Office: 08 Industrial Applications and Services)